Apogee Therapeutics, Inc. (APGE) Monday announced positive interim results from Phase 1 study of APG990.
The study is the first-in-human trial evaluating the safety, tolerability and pharmacokinetic (PK) of APG990 in healthy adult participants. APG990 demonstrated a potential best-in-class PK profile, including a half-life of about 60 days, supporting the potential for every three- and six-month maintenance dosing.
The results support potential for the company's planned combination study of APG777 and APG990, called APG279.
Apogee plans to submit an Investigational New Drug application or foreign equivalent for APG279. Following clearance, it expects to initiate a Phase 1b study in moderate-to-severe atopic dermatitis of APG279 against Dupixent this year. Data from the study is expected in the second half of 2025. Dupixent is the approved medicine of Sanofi and Regeneron to treat atopic dermatitis in adults.
For comments and feedback: editorial@rttnews.com